Small molecule drug poised to enter Phase I trials.
Debiopharm and Pharmaleads inked an exclusive license agreement for the development, registration, and commercialization of Debio 0827 or PL37, a small molecule about to enter Phase I trials. Debio 0827 is in a new class of painkillers that could be used in the treatment of chronic pain conditions, primarily in neuropathic pain.
Under the terms of the agreement, Debiopharm will make an upfront payment to Pharmaleads, as well as further payments as Pharmaleads reaches predefined development milestones.
“With this agreement we add the new therapeutic area of chronic pain management to the Debiopharm product portfolio. There is currently an unmet medical need for the treatment of chronic pain, which can often not be treated successfully and can seriously affect patients’ quality of life. For this reason, we have decided to develop this new therapeutic approach,” said Rolland-Yves Mauvernay, Ph.D., president and founder of Debiopharm Group.
